EE414 The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in the Netherlands
Dec 1, 2024, 00:00
10.1016/j.jval.2024.10.695
https://www.valueinhealthjournal.com/article/S1098-3015(24)03558-7/fulltext
Title :
EE414 The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in the Netherlands
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)03558-7&doi=10.1016/j.jval.2024.10.695
First page :
Section Title :
Open access? :
No
Section Order :
10187